S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 181 to 240 of 245

Issue Date	Title / Author(s) / Citation	File
2016-07	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer Han, Jae Joon; Kim, Dong-Wan; Koh, Jaemoon; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog Clinical Lung Cancer, Vol.17 No.4, pp.263-270	DOI
2016-07	The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: A meta-analysis Kim, Ryul; Hahn, Seokyung; Shin, Junghoon; Ock, Chan-Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Cancer Research and Treatment, Vol.48 No.3, pp.907-916	view file DOI
2016-08	An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone Nam, Soo Jeong; Kim, Sehui; Paik, Jin Ho; Kim, Tae Min; Heo, Dae Seog; Kim, Chul Woo; Jeon, Yoon Kyung Leukemia and Lymphoma, Vol.57 No.8, pp.1956-1960	DOI
2016-10	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma Kim, Ryul; Keam, Bhumsuk; Kwon, Dohee; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Hak Jae; Jeon, Yoon Kyung; Park, In Kyu; Kang, Chang Hyun; Kim, Dong-Wan; Kim, Young Tae; Heo, Dae Seog World Journal of Gastroenterology, Vol.22 No.37, pp.8389-8397	view file DOI
2016-11	Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations Park, Sehhoon; Park, Seongyeol; Lee, Se-Hoon; Suh, Beomseok; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.31 No.6, pp.1140-1149	view file DOI
2017-01	Post-bevacizumab clinical outcomes and the impact of early discontinuation of bevacizumab in patients with recurrent malignant glioma Cha, Yongjun; Kim, Yu Jung; Lee, Se-Hoon; Kim, Tae-Min; Choi, Seung Hong; Kim, Dong-Wan; Park, Chul-Kee; Kim, Il Han; Kim, Jee Hyun; Kim, Eunhee; Choi, Byungse; Kim, Chae-Yong; Kim, In Ah; Heo, Dae Seog Cancer Research and Treatment, Vol.49 No.1, pp.129-140	view file DOI
2017-01	Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications Paik, Jin Ho; Choe, Ji-Young; Kim, Hyojin; Lee, Jeong-Ok; Kang, Hyoung Jin; Shin, Hee Young; Lee, Dong Soon; Heo, Dae Seog; Kim, Chul-Woo; Cho, Kwang-Hyun; Kim, Tae Min; Jeon, Yoon Kyung Leukemia and Lymphoma, Vol.58 No.1, pp.53-63	DOI
2017-03	Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer Shin, Junghoon; Keam, Bhumsuk; Kim, Miso; Park, Young Sik; Kim, Tae Min; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog Journal of Thoracic Oncology, Vol.12 No.3, pp.520-528	DOI
2017-03	Optimal Timing of Influenza Vaccination During 3-Week Cytotoxic Chemotherapy Cycles Keam, Bhumsuk; Kim, Min-Kyung; Choi, Yunhee; Choi, Su-Jin; Choe, Pyoeng Gyun; Lee, Kyung-Hun; Kim, Tae Min; Kim, Tae-Yong; Oh, Do-Youn; Kim, Dong-Wan; Im, Seock-Ah; Kim, Nam-Joong; Heo, Dae Seog; Park, Wan Beom; Oh, Myoung-don Cancer, Vol.123 No.5, pp.841-848	DOI
2017-04	Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer Kim, Miso; Keam, Bhumsuk; Kim, Tae-Min; Kim, Hoon-Gu; Kim, Jin-Soo; Lee, Sung Sook; Shin, Seong Hoon; Kim, Min Kyoung; Park, Keon Uk; Kim, Dong-Wan; Yun, Hwan Jung; Lee, Jong Seok; Heo, Dae Seog Cancer Research and Treatment, Vol.49 No.2, pp.416-422	view file DOI
2017-05	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type Sim, Sung Hoon; Kim, Soyeon; Kim, Tae Min; Jeon, Yoon Kyung; Nam, Soo Jeong; Ahn, Yong-Oon; Keam, Bhumsuk; Park, Hyun Ho; Kim, Dong-Wan; Kim, Chul Woo; Heo, Dae Seog American Journal of Pathology, Vol.187 No.5, pp.980-986	DOI
2017-05	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer Park, Sehhoon; Kim, Ji-Yeon; Lee, Se-Hoon; Suh, Beomseok; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.32 No.3, pp.514-522	view file DOI
2017-06	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma Ock, Chan-Young; Kim, Sehui; Keam, Bhumsuk; Kim, Soyeon; Ahn, Yong-Oon; Chung, Eun-Jae; Kim, Jin-Ho; Kim, Tae Min; Kwon, Seong Keun; Jeon, Yoon Kyung; Jung, Kyeong Chun; Kim, Dong-Wan; Wu, Hong-Gyun; Sung, Myung Whun; Heo, Dae Seog Oncotarget, Vol.8 No.58, pp.97920-97927	view file DOI
2017-09	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas Lee, June-Koo; Lee, Junehawk; Kim, Sehui; Kim, Soyeon; Youk, Jeonghwan; Park, Seongyeol; An, Yohan; Keam, Bhumsuk; Kim, Dong-Wan; Heo, Dae Seog; Kim, Young Tae; Kim, Jin-Soo; Kim, Se Hyun; Lee, Jong Seok; Lee, Se-Hoon; Park, Keunchil; Ku, Ja-Lok; Jeon, Yoon Kyung; Chung, Doo Hyun; Park, Peter J.; Kim, Joon; Kim, Tae Min; Ju, Young Seok Journal of Clinical Oncology, Vol.35 No.26, pp.3065-3074	DOI
2017-10	Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate Lim, Yoojoo; Lim, Jee Min; Jeong, Won Jae; Lee, Kyung-Hun; Keam, Bhumsuk; Kim, Tae-Yong; Kim, Tae Min; Han, Sae-Won; Oh, Do Youn; Kim, Dong-Wan; Kim, Tae-You; Heo, Dae Seog; Bang, Yung-Jue; Im, Seock-Ah Cancer Research and Treatment, Vol.49 No.4, pp.1033-1043	view file DOI
2017-11	Diagnosis of secondary peripheral neurolymphomatosis: A multi-center experience Byun, Ja Min; Kim, Ki Hwan; Kim, Miso; Kim, Tae Min; Jeon, Yoon Kyung; Park, Jeong Hwan; Paik, Jin Ho; Lee, Jung Min; Lee, Ho-Young; Lee, Jong Seok; Heo, Dae Seog; Lee, Jeong-Ok Leukemia and Lymphoma, Vol.58 No.11, pp.2624-2632	DOI
2017-11	The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors Kim, Hyungjin; Park, Chang Min; Keam, Bhumsuk; Park, Sang Joon; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Goo, Jin Mo PLoS ONE, Vol.12 No.11, p. e0187500	view file DOI
2018-01	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor Park, Sehhoon; Ha, Seunggyun; Lee, Se-Hoon; Paeng, Jin Chul; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog PLoS ONE, Vol.13 No.1, p. e0189766	view file DOI
2018-03	Efficacy of pemetrexed-based chemotherapy in comparison to non-pemetrexed-based chemotherapy in advanced, ALK plus non-small cell lung cancer Jo, Jaemin; Kim, Se Hyun; Kim, Yu Jung; Lee, Juhyun; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Chung, Jin-Haeng; Jeon, Yoon Kyung; Lee, Jong Seok Yonsei Medical Journal, Vol.59 No.2, pp.202-210	view file DOI
2018-03	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody Suh, Koung Jin; Kim, Se Hyun; Kim, Yu Jung; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok Cancer Immunology, Immunotherapy, Vol.67 No.3, pp.459-470	DOI
2018-06	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Thoracic Cancer, Vol.9 No.6, pp.736-744	view file DOI
2018-07	The effect of hospice consultation on aggressive treatment of lung cancer Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Cancer Research and Treatment, Vol.50 No.3, pp.720-728	view file DOI
2018-08	Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Se Hyun; Kim, Yu Jung; Kim, Tae Min; Kim, Dong-Wan; Lee, Jong Seok; Heo, Dae Seog Esmo Open, Vol.3 No.5, p. e000332	DOI
2019	Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma Kang, Seong-Ho; Keam, Bhumsuk; Ahn, Yong-Oon; Park, Ha-Ram; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog OncoImmunology, Vol.8 No.1, p. e1515057	DOI
2019-01	A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma Kim, Miso; Kim, Tae Min; Keam, Bhumsuk; Kim, Yu Jung; Paeng, Jin Chul; Moon, Kyung Chul; Kim, Dong-Wan; Heo, Dae Seog Oncologist, Vol.24 No.1, pp.20-29	DOI
2019-01	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors Kim, Ryul; Keam, Bhumsuk; Kim, Sehui; Kim, Miso; Kim, Se Hyun; Kim, Jin Wook; Kim, Yu Jung; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Chung, Doo Hyun; Lee, Jong Seok; Heo, Dae Seog BMC Cancer, Vol.19 No.1, p. 19	view file DOI
2019-01	The risk of herpes zoster in patients with non-small cell lung cancer according to chemotherapy regimens: Tyrosine kinase inhibitors versus cytotoxic chemotherapy Choi, Ji Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Jo, Seong Jin Cancer Research and Treatment, Vol.51 No.1, pp.169-177	view file DOI
2019-01	Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small cell lung cancer Kim, Dong-Wan; Kim, Hoon-Gu; Kim, Joo-Hang; Park, Keunchil; Kim, Hoon-Kyo; Jang, Joung Soon; Kim, Bong-Seog; Kang, Jin-Hyoung; Lee, Kyung Flee; Kim, Sang-We; Ryoo, Hun Mo; Kim, Jin-Soo; Lee, Ki Hyeong; Kwon, Jung Hye; Choi, Jin-Hyuk; Shin, Sang Won; Hahn, Seokyung; Heo, Dae Seog Cancer Research and Treatment, Vol.51 No.1, pp.119-127	view file DOI
2019-05	Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients Yoo, Shin Hye; Keam, Bhumsuk; Ock, Chan-Young; Kim, Sehui; Han, Buhm; Kim, Ji-Won; Lee, Keun-Wook; Jeon, Yoon Kyung; Jung, Kyeong Cheon; Chung, Eun-Jae; Kwon, Seong Keun; Ahn, Soon-Hyun; Sung, Myung-Whun; Heo, Dae Seog Scientific Reports, Vol.9 No.1, p. 7680	DOI
2019-06	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors Park, Ha-Ram; Ahn, Yong-Oon; Kim, Tae Min; Kim, Soyeon; Kim, Seulki; Lee, Yu Soo; Kim, Miso; Keam, Bhumsuk; Kim, Dong-Wan; Heo, Dae Seog Cytotherapy, Vol.21 No.6, pp.603-611	DOI
2019-07	Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib Kim, Seulki; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Alm, Yong-Oon; Keam, Bhumsuk; Heo, Dae Seog Cancer Research and Treatment, Vol.51 No.3, pp.951-962	view file DOI
2019-07	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP Cho, Kyoung Min; Keam, Bhumsuk; Ha, Hyerim; Kim, Miso; Jung, Jae-Woo; Song, Woo-Jung; Kim, Tae Min; Jeon, Yoon Kyung; Kang, Hye-Ryun; Kim, Dong-Wan; Kim, Chul Woo; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.34 No.4, pp.885-893	view file DOI
2019-07	Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in ALK-rearranged lung cancer Kim, Su-Jung; Kim, Soyeon; Kim, Dong-Wan; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Lee, Yusoo; Koh, Jaemoon; Jeon, Yoon Kyung; Heo, Dae Seog Cancer Research and Treatment, Vol.51 No.3, pp.1231-1240	view file DOI
2019-07	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer Choi, Mihong; Keam, Bhumsuk; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Clinical Lung Cancer, Vol.20 No.4, pp.E442-E451	DOI
2019-08	Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study Jung, Minsun; Kim, Soyeon; Lee, June-Koo; Yoon, Sun Och; Park, Heae Surng; Hong, Soon Won; Park, Weon-Seo; Kim, Ji Eun; Kim, Joon; Keam, Bhumsuk; Kim, Hyun Jik; Kang, Hyoung Jin; Kim, Dong-Wan; Jung, Kyeong Cheon; Kim, Young Tae; Heo, Dae Seog; Kim, Tae Min; Jeon, Yoon Kyung Oncologist, Vol.24 No.8, pp.E740-E748	DOI
2019-09	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis Kim, Ryul; Keam, Bhumsuk; Hahn, Seokyung; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Clinical Lung Cancer, Vol.20 No.5, pp.331-338.e4	DOI
2019-09	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer Ock, Chan-Young; Yoo, Shin-Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong Wan; Chung, Doo Hyun; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.34 No.5, pp.1116-1124	view file DOI
2019-09	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog Journal of Thoracic Oncology, Vol.14 No.9, pp.1556-1566	DOI
2019-10	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer Kim, Yu-Jung; Keam, Bhumsuk; Ock, Chan-Young; Song, Sanghoon; Kim, Miso; Kim, Se Hyun; Kim, Ki Hwan; Kim, Jin-Soo; Kim, Tae Min; Kim, Dong-Wan; Lee, Jong Seok; Heo, Dae Seog Lung Cancer, Vol.136, pp.122-128	DOI
2019-11	Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment? Yoo, Shin Hye; Ock, Chan-Young; Keam, Bhumsuk; Park, Sung Joon; Kim, Tae Min; Kim, Jin Ho; Jeon, Yoon Kyung; Chung, Eun-Jae; Kwon, Seong Keun; Hah, J. Hun; Kwon, Tack-Kyun; Jung, Kyeong Chun; Kim, Dong-Wan; Wu, Hong-Gyun; Sung, Myung-Whun; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.34 No.6, pp.1313-1323	view file DOI
2019-11	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis Park, Changhee; Keam, Bhumsuk; Yoon, Soon Ho; Ock, Chan-Young; Choi, Sun Mi; Kim, Miso; Park, Young Sik; Kim, Tae Min; Oh, Do-Youn; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog; Bang, Yung-Jue Esmo Open, Vol.4 No.6, p. e000575	DOI
2019-11	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer Heo, Ja Yoon; Park, Changhee; Keam, Bhumsuk; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Kim, Se Hyun; Kim, Yu Jung; Lee, Jong Seok; Heo, Dae Seog Thoracic Cancer, Vol.10 No.11, pp.2117-2123	view file DOI
2019-11	Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer Kim, Sehui; Jang, Ji-Young; Koh, Jaemoon; Kwon, Dohee; Kim, Young A; Paeng, Jin Chul; Ock, Chan-Young; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Heo, Dae Seog; Chung, Doo Hyun; Jeon, Yoon Kyung Journal of Experimental & Clinical Cancer Research, 38(1):462	view file link
2020	Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines Park, Ji-Eun; Kim, Seong-Eun; Keam, Bhumsuk; Park, Ha-Ram; Kim, Soyeon; Kim, Miso; Kim, Tae Min; Doh, Junsang; Kim, Dong-Wan; Heo, Dae Seog Journal for ImmunoTherapy of Cancer, Vol.8 No.2, p. e000873	view file DOI
2020	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma Park, Changhee; Na, Kwon Joong; Choi, Hongyoon; Ock, Chan-Young; Ha, Seunggyun; Kim, Miso; Park, Samina; Keam, Bhumsuk; Kim, Tae Min; Paeng, Jin Chul; Park, In Kyu; Kang, Chang Hyun; Kim, Dong-Wan; Cheon, Gi-Jeong; Kang, Keon Wook; Kim, Young Tae; Heo, Dae Seog Theranostics, Vol.10 No.23, pp.10838-10848	view file DOI
2020-01	Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial Lee, Gyeong-Won; Go, Se-Il; Kim, Dong-Wan; Kim, Hoon-Gu; Kim, Joo-Hang; An, Ho Jung; Jang, Joung Soon; Kim, Bong-Seog; Hahn, Seokyung; Heo, Dae Seog Thoracic Cancer, Vol.11 No.1, pp.62-71	view file DOI
2020-03	Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies Park, Changhee; Kim, Miso; Kim, Min Jung; Kim, Hyeongmin; Ock, Chan-Young; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Kim, Jong-Il; Heo, Dae Seog Molecular Cancer Therapeutics, Vol.19 No.3, pp.937-944	view file DOI
2020-11	Immunophenotypic landscape and prognosis of diffuse large B-cell lymphoma with MYC/BCL2 double expression: An analysis of a prospectively immunoprofiled cohort Han, Bogyeong; Kim, Sehui; Koh, Jiwon; Yim, Jeemin; Lee, Cheol; Heo, Dae Seog; Kim, Tae Min; Paik, Jin Ho; Jeon, Yoon Kyung Cancers, Vol.12 No.11, pp.3305-15	DOI
2020-12	Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07 Kim, Miso; Keam, Bhumsuk; Ock, Chan-Young; Kim, Se Hyun; Kim, Yu Jung; Lim, Sun Min; Kim, Jin-Soo; Kim, Tae Min; Hong, Sook-Hee; Ahn, Mi Sun; Shin, Seong Hoon; Kang, Eun Joo; Kim, Dong-Wan; Im, Sun-Wha; Kim, Jong-Il; Lee, Jong Seok; Kim, Joo-Hang; Heo, Dae Seog Thoracic Cancer, Vol.11 No.12, pp.3482-3489	DOI
2020-12	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells Park, Siyeon; Kim, Tae Min; Cho, Sung-Yup; Kim, Soyeon; Oh, Yumi; Kim, Miso; Keam, Bhumsuk; Kim, Dong-Wan; Heo, Dae Seog Cancer Letters, Vol.495, pp.135-144	DOI
2021-01	Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients Heo, Ja Yoon; Yoo, Shin Hye; Suh, Koung Jin; Kim, Se Hyun; Kim, Yu Jung; Ock, Chan-Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok Scientific Reports, Vol.11 No.1, p. 2514	DOI
2021-02	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma Kang, Minsu; Park, Changhee; Kim, Se Hyun; Yoon, Sock Won; Suh, Koung Jin; Kim, Yu Jung; Ock, Chan-Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok Translational Lung Cancer Research, Vol.10 No.2, pp.699-711	DOI
2021-03	Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer Jung, Eun Hee; Jang, Hee Ryeong; Kim, Se Hyun; Suh, Koung Jin; Kim, Yu Jung; Lee, Ju-Hyun; Chung, Jin-Haeng; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok Thoracic Cancer, Vol.12 No.5, pp.619-630	DOI
2021-06	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy Park, Changhee; Jeong, Kyeonghun; Park, Joon-Hyeong; Jung, Sohee; Bae, Jeong Mo; Kim, Kwangsoo; Ock, Chan-Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Lee, Se-Hoon; Lee, Ju-Seog; Kim, Dong-Wan; Kang, Gyeong Hoon; Chung, Doo Hyun; Heo, Dae Seog Cancer Immunology, Immunotherapy, Vol.70 No.6, pp.1605-1617	DOI
2021-06	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues Yoo, Shin Hye; Yun, Jihui; Keam, Bhumsuk; Hong, Seung-Pyo; Ock, Chan-Young; Koh, Jaemoon; Kim, Sehui; Jeon, Yoon Kyung; Jung, Kyeong Cheon; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Kim, Jong-Il; Heo, Dae Seog Cancer Immunology, Immunotherapy, Vol.70 No.6, pp.1755-1769	DOI
2021-07	Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer Nam, Chang Hyun; Koh, Jaemoon; Ock, Chan-Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Chung, Doo Hyun; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.36 No.4, pp.975-984	DOI
2021-08	A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas Kim, Miso; Lee, Jeong-Ok; Koh, Jiwon; Kim, Tae Min; Lee, Ji Yun; Jeon, Yoon Kyung; Keam, Bhumsuk; Kim, Dong Wan; Lee, Jong Seok; Heo, Dae Seog Haematologica, Vol.106 No.8, pp.2277-2280
2021-10	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment Oh, So Yeon; Kim, Soyeon; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Scientific Reports, Vol.11 No.1, p. 19712
2021-11	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR(T790M)-Mutant NSCLC Park, Ha-Ram; Kim, Tae Min; Lee, Yusoo; Kim, Soyeon; Park, Seongyeol; Ju, Young Seok; Kim, Miso; Keam, Bhumsuk; Jeon, Yoon Kyung; Kim, Dong-Wan; Heo, Dae Seog Journal of Thoracic Oncology, Vol.16 No.11, pp.1859-1871	DOI
2022-01	Analysis of Cancer Patient Decision-Making and Health Service Utilization after Enforcement of the Life-Sustaining Treatment Decision-Making Act in Korea Kim, Dalyong; Yoo, Shin Hye; Seo, Seyoung; Lee, Hyun Jung; Kim, Min Sun; Shin, Sung Joon; Lim, Chi-Yeon; Kim, Do Yeun; Heo, Dae Seog; Lim, Chae-Man Cancer Research and Treatment, Vol.54 No.1, pp.20-29	DOI

1 2 3 4 5